Dharam Ablashi

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Source:LinkedIn

Dharam V. Ablashi, (b. 1931), DVM, MS, Dip. Bact. (Diploma in Bacteriology), Research Microbiologist, Head of DNA Viruses Section and Coordinator of DNA Viruses, National Cancer Institute.[1] He co-discovered Human herpesvirus 6 in 1986, while working at the National Cancer Institute at National Institutes of Health and is the Scientific Director of the HHV-6 Foundation and Chair of the Scientific Advisory Committee.[2]

Awards[edit | edit source]

  • 2007, Rudy Perpich Senior Lectureship Award, presented to a distinguished CFS/FM scientist, physician or healthcare worker awarded by IACFS/ME[3]
  • 2007, Achievement Award from New Jersey CFS Association Inc.[citation needed]

IACFS/ME[edit | edit source]

Ablashi co-founded the American Association of CFS with Orvalene Prewitt, in 1990.[4] The organization has been renamed as the International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis with Ablashi serving as a past President of the Board of Directors from 2003-2004.[5]

Advocacy[edit | edit source]

CFSAC testimony[edit | edit source]

Written presentation by Dr. Ablashi on October 29, 2009:"It is imperative that the CDC study biopsy samples from the gut, and brain as well as heart tissues, and that they look at spinal fluid. Most of the studies done by the CDC have been on serum. However, many pathogens cannot be found in the serum because they do not circulate in the peripheral blood after the initial infection."[6]

Open letters to The Lancet[edit | edit source]

In response to The Lancet's publication of the controversial PACE trial in 2011, three open letters to the editor of The Lancet urged the editor, Richard Horton, to commission a fully independent review of the PACE trial. Dr. Ablashi signed the second and third letters. The first, written in 2015, was signed by six ME/CFS experts.[7] In 2016, thirty-six additional colleagues in the ME/CFS field, signed the second letter.[8] In 2018, a resubmitted letter had over one hundred signatories.[9]

Notable studies in ME/CFS[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ Ablashi, Dharam. "Dharam Ablashi - Scientific Director at HHV-6 Foundation". Linked In.
  2. ↑ Ablashi, Dharam. "Scientific Office | HHV-6 Foundation | HHV-6 Disease Information for Patients, Clinicians, and Researchers | Apply for a Grant". hhv-6foundation.org. Retrieved August 16, 2018.
  3. ↑ "IACFS/ME Awardees". IACFS/ME. Retrieved April 23, 2020.
  4. ↑ "History of the IACFS/ME". IACFS/ME.
  5. ↑ "Committees of the IACFS/ME". IACFS/ME.
  6. ↑ "Biologisch Medisch Centrum | Dharam Ablashi Human Herpes Virus 6A (HHV-6 A) CFS/ME | Paul van Meerendonk Utrecht Epe". biologischmedischcentrumbmc.nl. Retrieved August 16, 2018.
  7. ↑ "An open letter to Dr. Richard Horton and The Lancet". Virology blog. Retrieved August 16, 2018.
  8. ↑ "An open letter to The Lancet, again". Virology blog. Retrieved August 16, 2018.
  9. ↑ "Trial By Error: Yet Another Appeal to The Lancet, With More On Board". Virology blog. Retrieved August 16, 2018.
  10. ↑ Tuller, David (November 13, 2015). "An open letter to Dr. Richard Horton and The Lancet". Virology blog. Retrieved August 16, 2018.
  11. ↑ Tuller, David (February 10, 2016). "An open letter to The Lancet, again". Virology blog. Retrieved August 16, 2018.
  12. ↑ Tuller, David (July 10, 2018). "Trial By Error: Yet Another Appeal to The Lancet, With More On Board". Virology blog. Retrieved August 16, 2018.
  13. ↑ Buchwald, Dedra; Cheney, Paul R.; Peterson, Daniel L.; Henry, Berch; Wormsley, Susan B.; Geiger, Ann; Ablashi, Dharam V.; Salahuddin, S. Zaki; Saxinger, Carl; Biddle, Royce; Kikinis, Ron; Jolesz, Ferenc A.; Folks, Thomas; Balachandran, N.; Peter, James B.; Gallo, Robert C.; Komaroff, Anthony L. (1992), "A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection", Annals of Internal Medicine, 116 (2): 103-113, PMID 1309285
  14. ↑ Levine, Paul H.; Jacobson, Steven; Pocinki, Alan G.; Cheney, Paul; Peterson, Daniel; Connelly, Roger R; Weil, R; Robinson, SM; Ablashi, Dharam V; Salahuddin, Sayeef Z; Pearson, GR; Hoover, R (1992), "Clinical, Epidemiologic, and Virologic Studies in Four Clusters of the Chronic Fatigue Syndrome", Archives of Internal Medicine, 152 (8): 1611-1616, doi:10.1001/archinte.1992.00400200049009
  15. ↑ Ablashi, DV; Berneman, ZN; Williams, M; Strayer, D; Kramarsky, B; Suhadolnik, RJ; Reichenbach, N; Hiltzges, P; Komaroff, AL (1994), "Ampligen inhibits human herpesvirus-6 in vitro", In Vivo, 8 (4): 587-91, PMID 7893986
  16. ↑ Strayer, DR; Carter, W; Strauss, KI; Brodsky, I; Suhadolnik, R; Ablashi, D; Henry, B; Mitchell, WM; Bastien, S; Peterson, D (1995), "Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen", Journal of Chronic Fatigue Syndrome, 1 (1): 35-53, doi:10.1300/J092v01n01_04
  17. ↑ Wagner, Mathias; Krueger, Gerhard R.F.; Ablashi, Dharam V.; Whitman, James E. (1996), "Chronic Fatigue Syndrome (CFS): A Critical Evaluation of Testing for Active Human Herpesvirus-6 (HHV-6) Infection, Review of Data of 107 Cases", Journal of Chronic Fatigue Syndrome, 2 (4): 3-16, doi:10.1300/J092v02n04_02
  18. ↑ Ablashi, Dharam V.; Ablashi, Kristine L.; Kramarsky, Bernhard; Bernbaum, John; Whitman, James E.; Pearson, Gary R. (1995), "Viruses and Chronic Fatigue Syndrome: Current Status", Journal of Chronic Fatigue Syndrome, 1 (2): 4-22, doi:10.1300/J092v01n02_02
  19. ↑ Levine, Susan; Eastman, Helen; Ablashi, Dharam V. (2001), "Prevalence of IgM and IgG Antibody to HHV-6 and HHV-8 and Results of Plasma PCR to HHV-6 and HHV-7 in a Group of CFS Patients and Healthy Donors", Journal of Chronic Fatigue Syndrome, 9 (1–2): 31-40, doi:10.1300/J092v09n01_04
  20. ↑ Cameron, Barbara; Hirschberg, David L.; Rosenberg-Hassan, Yael; Ablashi, Dharam; Lloyd, Andrew R. (2010), "Serum Cytokine Levels in Postinfective Fatigue Syndrome", Clinical Infectious Diseases, 50 (2): 278-280, doi:10.1086/649546

Chronic Fatigue Syndrome Advisory Committee (CFSAC) - (sometimes pronounced SIF-SACK) A US government advisory council that met twice per year, covering current topics related to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Meetings usually lasted for two days and the results were presented to the Secretary of Health and Human Services (HHS). After 15 years, on September 5, 2018, CFSAC's charter was not renewed by the Department of HHS, effectively dissolving the committee without notice or warning.

See Chronic fatigue syndrome advisory committee.

Centers for Disease Control and Prevention (CDC) - The Centers for Disease Control and Prevention is a U.S. government agency dedicated to epidemiology and public health. It operates under the auspices of the Department of Health and Human Services.

See Centers for Disease Control and Prevention.

The clear yellowish fluid that remains from blood plasma after clotting factors have been removed by clot formation. (Blood plasma is simply blood that has had its blood cells removed.)[1]

serum The clear yellowish fluid that remains from blood plasma after clotting factors have been removed by clot formation. (Blood plasma is simply blood that has had its blood cells removed.)

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

plasma The liquid part of blood, lymph, or milk after removing any suspended material. Most of the time, "plasma" simply refers to blood, after all the blood cells have been removed. If you also remove the clotting factors, then the plasma is referred to as "serum".

serum The clear yellowish fluid that remains from blood plasma after clotting factors have been removed by clot formation. (Blood plasma is simply blood that has had its blood cells removed.)

cytokine any class of immunoregulatory proteins secreted by cells, especially immune cells. Cytokines are small proteins important in cell signaling that modulate the immune system. (Learn more: me-pedia.org)

Retrieved from "https://me-pedia.org/w/index.php?title=Dharam_Ablashi&oldid=241619"